Vaxart (FRA:NB11) Cyclically Adjusted Revenue per Share: €0.57 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB11 Vaxart Inc FRA:NB11
50 GF Score
Price €0.38
! 3 Warning Signs
View Full Analysis

What is Vaxart Cyclically Adjusted Revenue per Share?

Vaxart FRA:NB11 50 Cyclically Adjusted Revenue per Share is €0.57 as of Mar. 2026. GuruFocus rates FRA:NB11 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vaxart's adjusted revenue per share for the three months ended in Mar. 2026 was €0.141. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.57 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vaxart's average Cyclically Adjusted Revenue Growth Rate was -31.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vaxart was 4.90% per year. The lowest was -37.90% per year. And the median was -24.20% per year.

As of today (2026-08-03), Vaxart's current stock price is €0.38. Vaxart's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.57. Vaxart's Cyclically Adjusted PS Ratio of today is 0.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vaxart was 1.49. The lowest was 0.02. And the median was 0.32.


Vaxart  (FRA:NB11) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vaxart's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.38/0.57
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vaxart was 1.49. The lowest was 0.02. And the median was 0.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vaxart Cyclically Adjusted Revenue per Share Related Terms


Vaxart Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vaxart's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Cyclically Adjusted Revenue per Share Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.87 0.00 3.47 1.59 1.21

Vaxart Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.00 1.18 1.21 0.57

FRA:NB11 vs VTVT, SPRB, ENGN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PS Ratio falls into.


FRA:NB11
50GF Score
Vaxart Inc FRA:NB11
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vaxart's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.141/330.2130*330.2130
=0.141

Current CPI (Mar. 2026) = 330.2130.

Vaxart Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.127 241.018 0.174
201609 0.025 241.428 0.034
201612 1.025 241.432 1.402
201703 1.304 243.801 1.766
201706 0.025 244.955 0.034
201709 0.024 246.819 0.032
201712 0.649 246.524 0.869
201803 0.230 249.554 0.304
201806 0.073 251.989 0.096
201809 0.034 252.439 0.044
201812 0.217 251.233 0.285
201903 0.655 254.202 0.851
201906 0.005 256.143 0.006
201909 0.025 256.759 0.032
201912 0.073 256.974 0.094
202003 0.043 258.115 0.055
202006 0.006 257.797 0.008
202009 0.002 260.280 0.003
202012 0.003 260.474 0.004
202103 0.004 264.877 0.005
202106 0.001 271.696 0.001
202109 0.001 274.310 0.001
202112 0.001 278.802 0.001
202203 0.001 287.504 0.001
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.002 301.836 0.002
202306 0.000 305.109 0.000
202309 0.003 307.789 0.003
202312 0.043 306.746 0.046
202403 0.012 312.332 0.013
202406 0.032 314.175 0.034
202409 0.020 315.301 0.021
202412 0.064 315.605 0.067
202503 0.085 319.799 0.088
202506 0.151 322.561 0.155
202509 0.270 324.800 0.274
202512 0.377 324.054 0.384
202603 0.141 330.213 0.141

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.57 mean?
Vaxart (FRA:NB11) has a Cyclically Adjusted Revenue per Share of €0.57 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vaxart and its competitors.
Is Vaxart's Cyclically Adjusted Revenue per Share too high?
Vaxart's current Cyclically Adjusted Revenue per Share is €0.57. Overall, Vaxart has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Cyclically Adjusted Revenue per Share compare to VTVT and SPRB?
Vaxart's Cyclically Adjusted Revenue per Share of €0.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vaxart and its competitors. Vaxart's current Cyclically Adjusted Revenue per Share is €0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (FRA:NB11) has a current Cyclically Adjusted Revenue per Share of €0.57. The current Cyclically Adjusted Revenue per Share is €0.57. Vaxart's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vaxart (FRA:NB11), the current Cyclically Adjusted Revenue per Share is €0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
50GF Score

Get the complete analysis for FRA:NB11

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price